



PRESS RELEASE

MolMed appoints Mr. Salvatore Calabrese Chief Financial Officer

Milan, September 11th 2018 – MolMed S.p.A. (MLMD.MI), (“the Company”) medical biotechnology company focusing on research, development, manufacturing, and clinical validation of Cell & Gene therapies to treat cancer and rare diseases, announces that as from today Mr. Salvatore Calabrese assumes the role of Chief Financial Officer of the Company, replacing Mr. Andrea Quaglino that, as announced on June 29th, will terminate his employment at the Company at the end of September.

Mr. Calabrese has an extensive and significant international experience in public companies and in the biopharmaceutical sector, starting from PriceWaterhouseCoopers where he was employed for seven years working in Milan, Italy and Boston, MA where, he served several clients of the biotech field listed on NASDAQ and NYSE, and subsequently at Novuspharma S.p.A., a subsidiary of Cell Therapeutics, Inc. (NASDAQ: CTIC), as Accounting & Finance Manager. From 2005 to 2014 he worked in Gentium S.p.A. (NASDAQ: GEN) where he was instrumental to the listing of the company on Nasdaq, covering various roles including Senior Vice President and Chief Financial Officer and Chief Operating Officer, supervising all of the company's corporate operations. Following the acquisition of Gentium by Jazz Pharmaceuticals (NASDAQ: JAZZ), he worked as General Manager and Site Leader for the Italian Operation at the Italian branch. He was also member of the Board of Directors of Gentium S.p.A. Jazz Pharmaceuticals Italy S.p.A. and Jazz Healthcare Italy S.r.l.

Commenting on the announcement, Dr. Riccardo Palmisano, Chief Executive Officer of MolMed S.p.A said, *“I am pleased to welcome Salvatore in MolMed and confident that thanks to his proven leadership and to his experience in the healthcare, finance and business strategy fields, he will represent a valuable asset to the future plans and growth of the Company. Also on Board of Directors behalf, I would like to thank Andrea once more for his dedication and competence demonstrated over the years spent with MolMed, and we wish him well in his future professional challenges”.*

Complete Salvatore Calabrese’s curriculum vitae is available on the Company's website www.molmed.com (in the Molmed / Company / management section).

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in



Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumors. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed's pipeline also includes NGR-hTNF, a therapeutic agent for solid tumors investigated in a broad clinical program, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti

Investor Relations & Communication Manager

MolMed S.p.A.

+39 02 21277.205

+39 02 21277.325

investor.relations@molmed.com

Marcella Ruggiero

Press agent

SEC Relazioni Pubbliche e Istituzionali s.r.l.

+39 02 6249991

+39 335 214241

ruggiero@secrp.com